Laurus Labs secures land for Pharma Zone; Sun Pharma, Dr. Reddy's, Alembic receive USFDA approvals; Zydus Lifesciences ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

In this video, Nancy U. Lin, MD, highlights practice-changing trials in the HER2-positive metastatic breast cancer space.

Delhi High Court refuses to direct Zydus to disclose manufacturing process of Sigrima: Gireesh Babu, New Delhi Saturday, July 26, 2025, 08:00 Hrs [IST] The Delhi High Court has sa ...

In this video, Nancy U. Lin, MD, discusses curative intent research in HER2-positive metastatic breast cancer.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

As researchers keep looking for ways to deescalate treatment in HER2-positive breast cancer, a trial from China looked at a chemotherapy-free regimen with endocrine therapy, a CDK4/6 inhibitor, and ...

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...